NEW YORK, March 23 (Reuters) - U.S. regulators have expanded the approval of Eli Lilly and Co's Symbyax, which combines the active ingredients of its Zyprexa antipsychotic and Prozac antidepressant, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback